专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO9513385A3 THROMBIN MUTANTS 审中-公开
标题翻译：血红蛋白
公开(公告)号：WO9513385A3
公开(公告)日：1996-02-01
申请号：PCT/US9413104
申请日：1994-11-14
申请人： GILEAD SCIENCES , GIBBS CRAIG S , LEUNG LAWRENCE L K , TSIANG MANUEL
发明人： GIBBS CRAIG S , LEUNG LAWRENCE L K , TSIANG MANUEL
IPC分类号： C12N15/09 , A61K38/00 , A61P7/02 , A61P9/00 , A61P9/08 , A61P9/10 , A61P35/00 , C07H21/04 , C12N5/10 , C12N9/74 , C12N15/57 , A61K38/48
CPC分类号： C12N9/6429 , A61K38/00 , C12Y304/21005
摘要： Thrombin mutants (Ts) are provided which are capable of protein C activation without significant fibrinogen clotting activity, and vice versa. Ts having enhanced protein C activating properties in relation to fibrinogen clotting are useful in particular as anticoagulants and in screening for substances that agonize or antagonize this property and in diagnostic procedures to determine the status of patients' activated protein C-mediated anticoagulant pathway. Procoagulant Ts are useful to promote clotting in the course of therapy of solid tumors, as an impregnate for bandages, or in diagnostic assays. The Ts are produced in recombinant cell culture or by in vitro methods.

3. 发明申请

WO1995013385A2 THROMBIN MUTANTS 审中-公开
标题翻译：血红蛋白
公开(公告)号：WO1995013385A2
公开(公告)日：1995-05-18
申请号：PCT/US1994013104
申请日：1994-11-14
申请人： GILEAD SCIENCES , GIBBS, Craig, S. , LEUNG, Lawrence, L., K. , TSIANG, Manuel
发明人： GILEAD SCIENCES
IPC分类号： C12N15/57
CPC分类号： C12N9/6429 , A61K38/00 , C12Y304/21005
摘要： Thrombin mutants (Ts) are provided which are capable of protein C activation without significant fibrinogen clotting activity, and vice versa. Ts having enhanced protein C activating properties in relation to fibrinogen clotting are useful in particular as anticoagulants and in screening for substances that agonize or antagonize this property and in diagnostic procedures to determine the status of patients' activated protein C-mediated anticoagulant pathway. Procoagulant Ts are useful to promote clotting in the course of therapy of solid tumors, as an impregnate for bandages, or in diagnostic assays. The Ts are produced in recombinant cell culture or by in vitro methods.
摘要翻译：提供凝血酶突变体（Ts），其能够蛋白C活化而没有明显的纤维蛋白原凝血活性，反之亦然。具有增强的与纤维蛋白原凝血相关的蛋白C活化性质的Ts尤其可用作抗凝剂，并且用于筛选激动或拮抗该性质的物质以及用于确定患者活化蛋白C介导的抗凝血途径状态的诊断程序。促凝剂Ts可用于在实体瘤治疗过程中促进凝血，作为绷带浸渍剂或诊断测定法。 Ts在重组细胞培养或体外方法中产生。

5. 发明申请

WO2005072748A1 USE OF ADEFOVIR OR TENOFOVIR FOR INHIBITING MMTV-LIKE VIRUSES INVOLVED IN BREAST CANCER AND PRIMARY BILIARY CIRRHOSIS 审中-公开
标题翻译：使用ADEFOVIR或TENOFOVIR抑制乳腺癌和原发性胆汁淤积相关的类似MMTV的病毒
公开(公告)号：WO2005072748A1
公开(公告)日：2005-08-11
申请号：PCT/US2005/002043
申请日：2005-01-21
申请人： GILEAD SCIENCES, INC. , CIHLAR, Tomas , DOUGLAS, Janet, L. , GIBBS, Craig, S.
发明人： CIHLAR, Tomas , DOUGLAS, Janet, L. , GIBBS, Craig, S.
IPC分类号： A61K31/675
CPC分类号： A61K45/06 , A61K31/675
摘要： The active metabolites of adefovir and tenofovir (PMEApp and PMPApp) are active against the MMTV RT. They are 25-fold more potent than 3TCppp, suggesting that tenofovir and adefovir may be effective at inhibiting the MMTV-like retroviruses, which may be the etiological agents involved in PBC and breast cancer.
摘要翻译：阿德福韦和替诺福韦（PMEApp和PMPApp）的活性代谢物对MMTV RT具有积极的作用。它们比3TCppp高25倍，表明替诺福韦和阿德福韦可能有效抑制MMTV样逆转录病毒，这可能是PBC和乳腺癌参与的病原体。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式